You just read:

Imfinzi® (durvalumab) is the First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer

News provided by

AstraZeneca Canada Inc.

Sep 12, 2019, 15:41 ET